Risk acceleration by gout on major adverse cardiovascular events and all‐cause death in patients with diabetes and chronic kidney disease
Authors' conclusion
CKD with or without gout increased the risk of CVD and mortality, with the highest risk observed in the CKD+Gout+ group. The interaction between CKD and gout significantly influenced these outcomes.
Study context
- Population
- Individuals with T2D, Korean National Health Insurance Service database
- Participants
- 757,378 individuals
- Exposure
- Gout and chronic kidney disease (CKD) status categories in T2D
- Outcome
- MI or stroke
- Follow-up
- Median 9.3 years
Methodological detailsnationwide database, Cox proportional hazard models adjusted for cardiometabolic factors
- Nationwide database
- Cox proportional hazard models adjusted for cardiometabolic factors
Main finding
As reported in the abstract
Each group vs CKD-Gout-Adjusted hazard ratio (95% CI)
CKD+Gout+
1.57(1.46–1.69)
CKD+Gout-
1.23(1.20–1.26)
Observational data: associations, not effects.
Further findings
| Outcome | Estimate |
|---|---|
| MI, stroke and mortality in CKD+Gout+CKD+Gout+ vs CKD-Gout- | HR (MI) 1.71 |
| MI, stroke and mortality in CKD+Gout+CKD+Gout+ vs CKD-Gout- | HR (stroke) 1.46 |
| MI, stroke and mortality in CKD+Gout+CKD+Gout+ vs CKD-Gout- | HR (mortality) 1.78 |
Events · median follow-up 9.3 years
- Myocardial infarction (MI)
- 25 618
- Stroke
- 38 691
- Mortality
- 78 628
Interaction of gout and CKD
- Effect of gout on outcomes more pronounced in patients with CKD
- Subgroup analyses consistent across demographic and clinical characteristics
Original publication
Risk acceleration by gout on major adverse cardiovascular events and all‐cause death in patients with diabetes and chronic kidney disease. Diabetes Obes Metab. Published 2 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →